Fziomed Announces FDA 510(k) Clearance for Dynavisc® Tendon Protector in the United States

FDA clearance expands Fziomed's U.S. portfolio of innovative, fully synthetic biomaterials for surgical applications.

SAN LUIS OBISPO, Calif., Nov. 18, 2026 /PRNewswire/ — Fziomed, Inc. (“Fziomed” or the “Company”), a global leader in postsurgical adhesion prevention biomaterials and surgical innovation, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Dynavisc® Tendon Protector. Dynavisc is a fully synthetic, ready-to-use, absorbable gel designed to protect tendons, ligaments, and skeletal muscle following surgical procedures.

Developed using Fziomed’s proprietary dual-polymer technology, Dynavisc is a clear, absorbable gel applied directly to the surgical site following tendon repair. Dynavisc coats exposed tissues, creating a temporary physical barrier that separates and protects adjacent tissues during the healing process, which may aid in reducing postoperative pain, preserving range of motion, and supporting functional recovery.

Sign up for Blog Updates